Business
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results
SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised
About this update from Sab Biotherapeutics, Inc.
[{"type":"text","content":"SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients Plans to announce full data from Phase 2a trial that evaluated SAB-176 for the treatment of seasonal influenza mid-2022 – first full clinical data set from DiversitAb platform SAB continues to advance on Rapid Response Antibody Program collaboration with US Department of Defense Generated robust data set, demonstrated proof-of-concept and validated platform through accelerated clinical development of SAB-185, a high-potency fully-human polyclonal therapeutic, to address pandemic need for novel treatments against emerging biothreats, respiratory viruses and viral mutations Sufficient cash and government funding anticipated to operate through third quarter 2023 SIOUX FALLS, S.D., March 29, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today provided a business update and reported financial results for the full year ended December 31, 2021.“2021 was a pivotal year for SAB Biotherapeutics, as we successfully closed our business combination and debuted on the NASDAQ exchange, while advancing SAB-185 and SAB-176, our novel polyclonal antibodies for COVID-19 and influenza. Our work on SAB-185 propelled our science forward with a real-world proof-of-concept. It contributed greatly to our scientific knowledge and gave us tremendous confidence in what SAB can achieve with our innovative technology to address a variety of acute and chronic unmet medical needs. It also demonstrated the potential of our rapid response platform to address future global public health threats. The historic impact of influenza and the evolving COVID-19 pandemic continues to impact at-risk patients, such as those with underlying conditions or those who are immunocompromised. The need for potent therapeutics remains clear,” said Eddie J. Sullivan, Ph.D., co-founder, President and Chief Executive Officer of SAB Biotherapeutics. “We are extremely proud of our team and SAB’s role in responding to the COVID-19 health crisis. SAB remains dedicated to rapidly developing therapies that can pl...